Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/122834
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
Author: Pagani, I.
Dang, P.
Saunders, V.
Grose, R.
Shanmuganathan, N.
Kok, C.
Carne, L.
Rwodzi, Z.
Watts, S.
McLean, J.
Braley, J.
Altamura, H.
Yeung, D.
Branford, S.
Yong, A.
White, D.
Hughes, T.
Ross, D.
Citation: Leukemia, 2020; 34(4):1052-1061
Publisher: Springer Nature
Issue Date: 2020
ISSN: 0887-6924
1476-5551
Statement of
Responsibility: 
Ilaria S. Pagani, Phuong Dang, Verity A. Saunders, Randall Grose, Naranie Shanmuganathan, Chung H. Kok … et al.
Abstract: Approximately half of patients with chronic myeloid leukemia (CML) in sustained deep molecular response who discontinue tyrosine kinase inhibitors (TKIs) remain in treatment-free remission (TFR). Some of these patients have measurable residual disease (MRD) by BCR-ABL1 mRNA testing, and most have detectable BCR-ABL1 DNA by highly sensitive methods. We used fluorescence-activated cell sorting and BCR-ABL1 DNA PCR to investigate the lineage of residual CML cells in TFR. Twenty patients in TFR for >1 year provided blood for sorting into granulocytes, monocytes, B cells, T cells, and NK cells. MRD was identified predominantly in the lymphoid compartment and never in granulocytes. B cells were more often BCR-ABL1 positive than T cells (18 vs 11/20 patients) and at higher levels (median 10-4.9 vs 10-5.7; P = 0.014). In 13 CML patients studied at diagnosis lymphocytes expressing BCR-ABL1 mRNA comprised a small proportion of total leukocytes. These data improve our understanding of TFR biology, since it is now clear that MRD in the blood of TFR patients need not imply the persistence of multipotent CML cells. Lineage-specific assessment of MRD could be explored as a means to improve the prediction of TFR.
Keywords: Lymphocyte Subsets; Humans; Neoplasm, Residual; Fusion Proteins, bcr-abl; Protein Kinase Inhibitors; Prognosis; Remission Induction; Follow-Up Studies; Cell Lineage; Adult; Aged; Aged, 80 and over; Middle Aged; Female; Male; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Imatinib Mesylate
Description: Published: 25 November 2019
Rights: © The Author(s), under exclusive licence to Springer Nature Limited 2019.
RMID: 1000006485
DOI: 10.1038/s41375-019-0647-x
Grant ID: http://purl.org/au-research/grants/nhmrc/1138935
http://purl.org/au-research/grants/nhmrc/1104425
http://purl.org/au-research/grants/nhmrc/1051965
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.